Rapidly progressive dementia - Insights
Mayo Clinic Laboratories’ first-in-class testing for rapidly progressive dementia and Creutzfeldt-Jakob disease uses a sensitive and specific seed amplification assay that detects and identifies prion proteins in CSF alongside a clinically...
Learn more about how Mayo Clinic Laboratories helps hospital laboratories reduce costs and grow revenue.
Precision oncology therapeutics - Insights
Learn more about our personalized cancer testing that establishes patients’ genetic profiles and allows physicians to select medications that optimize therapeutic efficacy while minimizing harmful reactions.
Inborn errors of metabolism - Insights
Learn more about how Mayo Clinic Laboratories’ comprehensive menu of biochemical and molecular testing can diagnose inborn errors of metabolism.
At BioPharma Diagnostics, we are inspired by Mayo Clinic’s history of collaboration and breaking down barriers to change medicine. That’s why we bring Mayo Clinic expertise and quality to each project — from consulting through discovery to...
Whole genome sequencing - Insights
Check out Mayo Clinic Laboratories’ whole genome testing, a next-generation sequencing assay that interrogates nearly every base pair of an individual’s DNA, including the mitochondrial genome.
Mayo Clinic Laboratories offers a robust menu of biomarker testing to assess liver disease related to nonalcoholic and alcoholic causes. These include FibroTest-ActiTest, a first-line screening assay that uses two diagnostic scores based on...
New tests launched in January - Insights
In January 2022, Mayo Clinic Laboratories announced twenty five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Find out how our hereditary cancer panels use next-generation sequencing to evaluate dozens of genes associated with cancer risk.
Demyelinating disease - Insights
Learn about our demyelinating disease testing, including multiple sclerosis, AQP4/MOG-associated disorders, and spinal cord disorders.